Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Brands2Life launches pharma tech offer with MHP hire
Brands2Life appoints Isabelle Scali as head of pharma to lead new service aiding pharmaceutical companies in navigating health and technology, aiming for more agile and creative healthcare communications.
CEACAM5 Drugs Market Outlook: Rising Cancer Cases and Clinical Trials to Fuel Growth by 2034
CEACAM5 drugs market to grow significantly due to rising cancer diagnoses and clinical trials; no CEACAM5 drugs currently approved. Key companies developing CEACAM5 drugs include Merck KGaA, Sanofi, and Roche. Emerging therapies like SGM-101 and M9140 show promise in clinical trials.
Survival Win for Pembrolizumab in Early Triple-Negative Breast Cancer
PD-1 inhibition with pembrolizumab before and after surgery significantly improves 5-year overall survival (86.6% vs 81.7%) in high-risk early triple-negative breast cancer, according to KEYNOTE-522 trial results.
BioMarin's Rare Disease Portfolio Supports a Narrow Economic Moat
BioMarin's genetic-disease therapeutics portfolio mirrors Genzyme's historical trajectory. Despite years of red ink from commercialization and R&D expenses, its current portfolio's profit-generating potential is robust, bolstered by a deep pipeline and strategic acquisitions.
Sanofi, AstraZeneca Get FDA Approval of New Manufacturing Line to Bolster US Supply of Beyfortus
FDA approves Sanofi and AstraZeneca's new filling line for Beyfortus, enabling expanded manufacturing capacity and supply in the U.S. for the 2024/2025 RSV season. Beyfortus, a long-acting antibody, was FDA-approved in July 2023 for infants and children up to 24 months old at severe risk of RSV infection. CDC analysis in March 2024 showed Beyfortus 90% effective at preventing RSV hospitalization.
Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
Kura Oncology appoints Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles brings over 25 years of oncology drug development experience and industry leadership, enhancing Kura's menin inhibitor and farnesyl transferase inhibitor programs.
Sanofi/Regeneron's Dupixent granted FDA approval for adolescents with CRSwNP
Sanofi and Regeneron’s Dupixent approved by FDA as add-on maintenance treatment for adolescents with chronic rhinosinusitis with nasal polyps (CRSwNP), ages 12-17, expanding previous approval for ages 18 and older. Dupixent, a monoclonal antibody, inhibits interleukin-4 and interleukin-13 pathways, improving symptoms and reducing need for systemic corticosteroids or surgery.
FDA approves manufacturing line for RSV therapy
Sanofi received FDA approval for a new manufacturing line to expand production of Beyfortus, a preventive therapy for RSV in infants. Beyfortus is the first long-acting monoclonal antibody approved by the FDA to prevent RSV-related lower respiratory tract disease in newborns and infants up to 24 months old. Sanofi has begun shipping doses to private healthcare providers and the CDC's Vaccines for Children program.
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
FDA approves Regeneron's Dupixent for chronic rhinosinusitis with nasal polyps in adolescents aged 12-17, expanding its initial approval for adults. This expansion is supported by positive trial data showing significant improvements in symptoms and reduced need for corticosteroids or surgery.
© Copyright 2025. All Rights Reserved by MedPath